Varshasb Broumand, MD
Nephrology · San Antonio, TXNPI 1154329720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,077 of the $117,819 with a category attached, or 60.3%. 45 manufacturers reported payments, led by Outset Medical Inc at 36.4% of the total. Reporting peaked in 2023 at $33,686 and has fallen 58.8% since, to $13,878 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 911 payments — averaging $129.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$43K
- OPKO Pharmaceuticals, LLC$34K
- Vifor Pharma, Inc.$9K
- Bayer$9K
- Akebia Therapeutics Inc$7K
- Amgen$6K
- plus $10K from 39 others
Across 178 payments — averaging $2359.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$180K
- Grifols, S.A.$136K
- GSK$94K
- AstraZeneca$10K
What the payments were for
- Consulting fees$22,10319%
- Speaking & faculty fees$71,07760%
- Travel & lodging$5,1504%
- Food & beverage$19,13416%
- Education$2390%
- Entertainment$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,819 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 140 | $261,933 |
| FarxigaDapagliflozin Propanediol | 208 | $207,536 |
| KerendiaFinerenone | 144 | $173,418 |
| OzempicSemaglutide | 99 | $113,048 |
| ProcritEpoetin Alfa | 53 | $111,445 |
| MounjaroTirzepatide | 64 | $95,110 |
| JanuviaSitagliptin Phosphate | 55 | $85,835 |
| VelphoroSucroferric Oxyhydroxide | 21 | $85,118 |
| VeltassaPatiromer Calcium Sorbitex | 48 | $77,371 |
| JardianceEmpagliflozin | 31 | $54,177 |
| XphozahTenapanor Hcl | 16 | $45,677 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $37,750 |
| TrulicityDulaglutide | 20 | $34,345 |
| AuryxiaFerric Citrate | 16 | $23,999 |
| EntrestoSacubitril/Valsartan | 14 | $23,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $33,631 | $261,933140 claims |
| AstraZenecaFarxiga, Lokelma | $1,126 | $245,286230 claims |
| BayerKerendia | $9,090 | $173,418144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $204 | $129,45684 claims |
| Novo NordiskOzempic | $361 | $113,04899 claims |
| Fresenius USA Marketing, Inc.Velphoro | $944 | $85,11821 claims |
| Boehringer IngelheimJardiance | $63 | $54,17731 claims |
| Akebia Therapeutics IncAuryxia | $7,158 | $23,99916 claims |
| NovartisEntresto | $551 | $23,46014 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $307 | $2,16491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Luis VelezSan Antonio$505K
- Rashid SharafSan Antonio$340K
- Carl DukesSan Antonio$238K
- Pablo PergolaSan Antonio$164K
- Shweta BansalSan Antonio$89K
- Rajeev NarayanSan Antonio$57K
- Anwar GergesSan Antonio$50K
- Matthew SchaeferSan Antonio$46K
- Kumar SharmaSan Antonio$45K
- Gerardo ChicaSan Antonio$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.